Benchmark processes first batch of commercial-scale antigen

Liza Mayer
January 17, 2018
By Liza Mayer
Late in October Benchmark announced that its first commercial-scale batch of antigen has been processed at its facility in Braintree, UK.

The antigen will be used in a number of new aquaculture vaccines in Benchmark’s product pipeline.

Work on the final validation of the $22 million biotechnology building, to ensure compliance with EU Good Manufacturing Practices (GMP) is underway. Once fully licensed the increased capacity will allow Benchmark to expand the number and range of vaccines it produces.

According to Benchmark, the 2,500-square-metre facility is set to be one of the most capable EU GMP antigen production facilities in Europe.

Add comment


Security code
Refresh

Subscription Centre

 
New Subscription
 
Already a Subscriber
 
Customer Service
 
View Digital Magazine Renew

Most Popular

Latest Events

Laqua 18
Tue Oct 23, 2018
Aquaculture 2019
Thu Mar 07, 2019

We are using cookies to give you the best experience on our website. By continuing to use the site, you agree to the use of cookies. To find out more, read our Privacy Policy.